Optimum Investment Advisors Incyte Corp Transaction History

Optimum Investment Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 21, 2021	SELL	$80.74 - $97.7 $8,073 - $9,770	-100 Closed	0 $0
Q3 2020 Oct 06, 2020	SELL	$85.07 - $109.69 $34,028 - $43,876	-400 Reduced 80.0%	100 $9,000
Q4 2019 Jan 22, 2020	BUY	$73.04 - $95.72 $7,304 - $9,572	100 Added 25.0%	500 $44,000
Q3 2019 Oct 17, 2019	SELL	$72.82 - $86.52 $7,281 - $8,652	-100 Reduced 20.0%	400 $30,000
Q2 2018 Oct 05, 2018	SELL	$60.85 - $83.98 $73,020 - $100,776	-1,200 Reduced 70.59%	500 $34,000
Q1 2018 May 09, 2018	BUY	$83.06 - $100.98 $141,202 - $171,666	1,700 New	1,700 $142,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Optimum Investment Advisors, based on Form 13F filings with the SEC.

Stay updated on Optimum Investment Advisors with notifications on news.